883559-96-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-3-(methylamino)benzamide is used as a key intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and medications.
Used in Dye and Pigment Industry:
4-aMino-3-(MethylaMino)benzaMide is utilized in the manufacturing of dyes, pigments, and other colorants, playing a crucial role in the production of a wide range of colored products.
Used in Research and Development:
4-Amino-3-(methylamino)benzamide is employed as a reagent in organic chemical reactions, aiding researchers and scientists in the exploration and development of new chemical compounds and their potential applications.

Upstream product

• 214778-10-6 3-methylamino-4-nitro-benzoic acid 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 

Relevant academic research and scientific papers

Methods for Chk2 inhibitor patient selection

The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids, such as silencing interference RNA's specific for a Chk2 expression. Other Chk2 inhibitors may comprises proteins, such as antibodies. For example, the present invention contemplates that when a Chk2 inhibitor is administered during, or after, ionizing radiation tumor cell apoptosis is increased.

Novel non-benzimidazole chk2 kinase inhibitors

In a recent paper, [Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K. M.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Chennagiri, R. P.; Karlsson, L.; Brietenbucher, J. G. J. Med. Chem. 2005, 48, 1873], we described the discovery of a class of benzimidazole chk2 kinase inhibitors, exemplified by compound 1, which had radio-protective effects in human T-cells subjected to ionizing radiation. Here, a series of non-benzimidazole analogs intended to define the scope of the SAR about this new series of inhibitor, and allow for refinement of the binding model of these compounds to the chk2 kinase is described.